174 related articles for article (PubMed ID: 23562056)
1. Conformational restriction approach to BACE1 inhibitors II: SAR study of the isocytosine derivatives fixed with a cis-cyclopropane ring.
Yonezawa S; Yamakawa H; Muto C; Hosono M; Yamamoto T; Hattori K; Sakagami M; Togame H; Tanaka Y; Nakano T; Takemoto H; Arisawa M; Shuto S
Bioorg Med Chem Lett; 2013 May; 23(10):2912-5. PubMed ID: 23562056
[TBL] [Abstract][Full Text] [Related]
2. Conformational restriction approach to β-secretase (BACE1) inhibitors: effect of a cyclopropane ring to induce an alternative binding mode.
Yonezawa S; Yamamoto T; Yamakawa H; Muto C; Hosono M; Hattori K; Higashino K; Yutsudo T; Iwamoto H; Kondo Y; Sakagami M; Togame H; Tanaka Y; Nakano T; Takemoto H; Arisawa M; Shuto S
J Med Chem; 2012 Oct; 55(20):8838-58. PubMed ID: 22998419
[TBL] [Abstract][Full Text] [Related]
3. Conformational restriction approach to β-secretase (BACE1) inhibitors III: effective investigation of the binding mode by combinational use of X-ray analysis, isothermal titration calorimetry and theoretical calculations.
Yonezawa S; Fujiwara K; Yamamoto T; Hattori K; Yamakawa H; Muto C; Hosono M; Tanaka Y; Nakano T; Takemoto H; Arisawa M; Shuto S
Bioorg Med Chem; 2013 Nov; 21(21):6506-22. PubMed ID: 24051074
[TBL] [Abstract][Full Text] [Related]
4. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design.
Hamada Y; Tagad HD; Nishimura Y; Ishiura S; Kiso Y
Bioorg Med Chem Lett; 2012 Jan; 22(2):1130-5. PubMed ID: 22178553
[TBL] [Abstract][Full Text] [Related]
5. Carbazole-containing arylcarboxamides as BACE1 inhibitors.
Bertini S; Asso V; Ghilardi E; Granchi C; Manera C; Minutolo F; Saccomanni G; Bortolato A; Mason J; Moro S; Macchia M
Bioorg Med Chem Lett; 2011 Nov; 21(22):6657-61. PubMed ID: 21986588
[TBL] [Abstract][Full Text] [Related]
6. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).
Cheng Y; Judd TC; Bartberger MD; Brown J; Chen K; Fremeau RT; Hickman D; Hitchcock SA; Jordan B; Li V; Lopez P; Louie SW; Luo Y; Michelsen K; Nixey T; Powers TS; Rattan C; Sickmier EA; St Jean DJ; Wahl RC; Wen PH; Wood S
J Med Chem; 2011 Aug; 54(16):5836-57. PubMed ID: 21707077
[TBL] [Abstract][Full Text] [Related]
7. A stereoselective approach to peptidomimetic BACE1 inhibitors.
Butini S; Gabellieri E; Brindisi M; Giovani S; Maramai S; Kshirsagar G; Guarino E; Brogi S; La Pietra V; Giustiniano M; Marinelli L; Novellino E; Campiani G; Cappelli A; Gemma S
Eur J Med Chem; 2013; 70():233-47. PubMed ID: 24158015
[TBL] [Abstract][Full Text] [Related]
8. Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
Winneroski LL; Erickson JA; Green SJ; Lopez JE; Stout SL; Porter WJ; Timm DE; Audia JE; Barberis M; Beck JP; Boggs LN; Borders AR; Boyer RD; Brier RA; Hembre EJ; Hendle J; Garcia-Losada P; Minguez JM; Mathes BM; May PC; Monk SA; Rankovic Z; Shi Y; Watson BM; Yang Z; Mergott DJ
Bioorg Med Chem; 2020 Jan; 28(1):115194. PubMed ID: 31786008
[TBL] [Abstract][Full Text] [Related]
9. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor.
Cumming JN; Smith EM; Wang L; Misiaszek J; Durkin J; Pan J; Iserloh U; Wu Y; Zhu Z; Strickland C; Voigt J; Chen X; Kennedy ME; Kuvelkar R; Hyde LA; Cox K; Favreau L; Czarniecki MF; Greenlee WJ; McKittrick BA; Parker EM; Stamford AW
Bioorg Med Chem Lett; 2012 Apr; 22(7):2444-9. PubMed ID: 22390835
[TBL] [Abstract][Full Text] [Related]
10. Thiophene substituted acylguanidines as BACE1 inhibitors.
Fobare WF; Solvibile WR; Robichaud AJ; Malamas MS; Manas E; Turner J; Hu Y; Wagner E; Chopra R; Cowling R; Jin G; Bard J
Bioorg Med Chem Lett; 2007 Oct; 17(19):5353-6. PubMed ID: 17761418
[TBL] [Abstract][Full Text] [Related]
11. New pyrazolyl and thienyl aminohydantoins as potent BACE1 inhibitors: exploring the S2' region.
Malamas MS; Erdei J; Gunawan I; Barnes K; Hui Y; Johnson M; Robichaud A; Zhou P; Yan Y; Solvibile W; Turner J; Fan KY; Chopra R; Bard J; Pangalos MN
Bioorg Med Chem Lett; 2011 Sep; 21(18):5164-70. PubMed ID: 21835615
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of curcumin derivatives toward an inhibitor of beta-site amyloid precursor protein cleaving enzyme 1.
Konno H; Endo H; Ise S; Miyazaki K; Aoki H; Sanjoh A; Kobayashi K; Hattori Y; Akaji K
Bioorg Med Chem Lett; 2014 Jan; 24(2):685-90. PubMed ID: 24360557
[TBL] [Abstract][Full Text] [Related]
13. Pyridinyl aminohydantoins as small molecule BACE1 inhibitors.
Zhou P; Li Y; Fan Y; Wang Z; Chopra R; Olland A; Hu Y; Magolda RL; Pangalos M; Reinhart PH; Turner MJ; Bard J; Malamas MS; Robichaud AJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2326-9. PubMed ID: 20202842
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of thiophene dihydroisoquinolines as novel BACE1 inhibitors.
Xu YZ; Yuan S; Bowers S; Hom RK; Chan W; Sham HL; Zhu YL; Beroza P; Pan H; Brecht E; Yao N; Lougheed J; Yan J; Tam D; Ren Z; Ruslim L; Bova MP; Artis DR
Bioorg Med Chem Lett; 2013 May; 23(10):3075-80. PubMed ID: 23570791
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors.
Thompson LA; Shi J; Decicco CP; Tebben AJ; Olson RE; Boy KM; Guernon JM; Good AC; Liauw A; Zheng C; Copeland RA; Combs AP; Trainor GL; Camac DM; Muckelbauer JK; Lentz KA; Grace JE; Burton CR; Toyn JH; Barten DM; Marcinkeviciene J; Meredith JE; Albright CF; Macor JE
Bioorg Med Chem Lett; 2011 Nov; 21(22):6909-15. PubMed ID: 21974952
[TBL] [Abstract][Full Text] [Related]
16. Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease.
Linning P; Haussmann U; Beyer I; Weidlich S; Schieb H; Wiltfang J; Klafki HW; Knölker HJ
Org Biomol Chem; 2012 Oct; 10(41):8216-35. PubMed ID: 22930158
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of (3S,4S)-4-aminopyrrolidine-3-ol derivatives and biological evaluation for their BACE1 inhibitory activities.
De Tran Q; Bepary S; Lee GH; Cho H; Park WK; Lim HJ
Bioorg Med Chem Lett; 2016 Jan; 26(1):51-4. PubMed ID: 26608551
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship study of BACE1 inhibitors possessing a chelidonic or 2,6-pyridinedicarboxylic scaffold at the P(2) position.
Hamada Y; Suzuki K; Nakanishi T; Sarma D; Ohta H; Yamaguchi R; Yamasaki M; Hidaka K; Ishiura S; Kiso Y
Bioorg Med Chem Lett; 2014 Jan; 24(2):618-23. PubMed ID: 24360554
[TBL] [Abstract][Full Text] [Related]
19. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.
Edwards PD; Albert JS; Sylvester M; Aharony D; Andisik D; Callaghan O; Campbell JB; Carr RA; Chessari G; Congreve M; Frederickson M; Folmer RH; Geschwindner S; Koether G; Kolmodin K; Krumrine J; Mauger RC; Murray CW; Olsson LL; Patel S; Spear N; Tian G
J Med Chem; 2007 Nov; 50(24):5912-25. PubMed ID: 17985862
[TBL] [Abstract][Full Text] [Related]
20. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors.
Rueeger H; Rondeau JM; McCarthy C; Möbitz H; Tintelnot-Blomley M; Neumann U; Desrayaud S
Bioorg Med Chem Lett; 2011 Apr; 21(7):1942-7. PubMed ID: 21388807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
